M1 Kliniken

M1 Kliniken is concentrating fully on the profitable beauty segment after selling its pharma business, which grew by 11% in H1 to €56.9m. Segment EBIT rose 23.8% to €18.6m and the margin climbed to 32.7%; management targets 2029 revenue of €200–300m and an EBIT margin of at least 20%. With a major shareholder (MPH Health Care) holding over 66% and low free float, M1 Kliniken is seen as an attractive takeover or going-private candidate; a price target of €26.50 (about 31% upside) is cited. » Más en finanzen.net

Adjusted figures show M1 Kliniken’s core business increased revenue in H1 2026 by 11% to €56.9m and improved EBIT by almost 24% to €18.6m; in Q2 revenue growth accelerated to around 16%. The prior sharp decline in group metrics resulted from the deconsolidation and sale of wholesale subsidiary Haemato Pharm. Management confirms a mid-term target of €200–300m revenue by 2029 with an EBIT margin of at least 20% (H1 margin: >32%). Analysts raised the price target, leaving upside of almost 50%; the P/E for 2026 is expected to be below 14. » Más en finanzen.net

M1 Kliniken's stock has risen in recent months to close to its all-time high. The Düsseldorf-based company reports robust growth and surprised with a significantly increased dividend. If the ambitious forecasts are met, the authors see further upside potential for the share price. » Más en finanzen.net